Application of pharmacogenetics to the therapeutics of asthma

Therapeutic Targets in Airway Inflammation

Volumn , Issue , 2003, Pages 823-838

  Silverman, Eric S ^a   Hjoberg, Josephine ^a   Palmer, Lyle J ^a   Weiss, Scott T ^a   Drazen, Jeffrey M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056935159     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (35)

1. Barnes PJ, Thomson NC, Rodger IW. Preface. In: Barnes PJ, Rodger IW, Thomson NC, eds. Asthma: Basic Mechanisms and Clinical Management, 3rd ed. San Diego, CA: Academic Press, 1998.
2. Sullivan SD, Weiss KB. Pharmacoeconomics of asthma treatments. In: Barnes PJ, Rodger IW, Thomson NC, eds. Asthma: Basic Mechanisms and Clinical Management, 3rd ed. San Diego, CA: Academic Press, 1998:903-916.
3. American Lung Association’s Epidemiology and Statistics Unit. Trends in asthma morbidity and mortality. Vol. 2001: American Lung Association, 2001. Accessed online atwww.lungusa.org.
4. NHLBI/WHO Workshop. Global initiative from asthma management and prevention. National Institutes of Health, National Heart, Lung, and Blood Institute and the World Health Organization, 1998. Accessed online at www.ginasthma.com.
5. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000; 56:1054-1070.
6. Liggett SB. Pharmacogenetic applications of the Human Genome Project. Nat Med2001; 7:281-283.
7. Leeder JS. Pharmacogenetics and pharmacogenomics. Pediatr Clin North Am 2001; 48: 765-781.
8. Kalow W. Familial incidence of low pseudocholinesterase level. Lancet 1956; 271:576.
9. Hughes HB, Biehl JP, Jones AP, Schmidt LH. Metabolish of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc 1954; 70:266-273.
10. Drazen JM, Israel E, Boushey HA, Chinchilli VM, Fahy JV, Fish JE, Lazarus SC, Lemanske RF, Martin RJ, Peters SP, Sorkness C, Szefler SJ. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996; 335:841-847.
11. The International SNP Map Working Group. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409: 928-933.
12. Brookes AJ. The essence of SNPs. Gene 1999; 234:177-186.
13. Ingelman-Sundberg M. Pharmacogenetics: An opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001; 250:186-200.
14. Elston RC. The genetic dissection of multifactorial traits. Clin Exp Allergy 1995; 25(suppl 2): 103-106.
15. Silverman EK, Palmer LJ. Case-control association studies for the genetics of complex respiratory diseases. Am J Respir Cell Mol Biol 2000; 22:645-648.
16. Clark DA, Weiss KM, Nickerson DA, Taylor SL, Buchanan A, Stengard J, Salomaa V, Vartiainen E, Perola M, Boerwinkle E, Sing CF. Haplotype structure and population genetic inferences from nucleotide-sequence variation in human lipoprotein lipase. Am J Human Genet 1998; 63:595-612.
17. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999; 65:220-228.
18. Samuelson B. leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220:568-575.
19. Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, Gillard JW, Miller DK. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature1990; 343:282-284.
20. Samuelsson B, Funk CD. Enzymes involved in the biosynthesis of leukotriene B4. J Biol Chem 1989; 264:19469-19472.
21. Yoshimoto T, Soberman RJ, Lewis RA, Austen KF. Isolation and characterization of leukotriene C4 synthetase of rat basophilic leukemia cells. Proc Natl Acad Sci USA1985; 82:8399-8403.
22. Lam BK, Owen WF, Jr., Austen KF, Soberman RJ. The identification of a distinct export step following the biosynthesis of leukotriene C4 by human eosinophils. J Biol Chem 1989; 264:12885-12889.
23. Drazen JM. Cysteinyl leukotrienes. In: Barnes PJ, Rodger IW, Thomson NC, eds.Asthma: Basic Mechanisms and Clinical Management, 3rd ed. San Diego, CA: Academic Press, 1998:281-295.
24. Lynch KR, O’Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, Coulombe N, Abramovitz M, Figueroa DJ, Zeng Z, Connoly BM, Bai C. Austin CP, Chateauneuf A, Stocco R, Greig GM, Kargman S, Hooks SB, Hosfield E, Williams DR, Ford-Hutchinson AW, Caskey CT, Evans JF. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399:789-793.
25. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990; 323:645-655.
26. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapy. J Allergy Clin Immunol 1996; 98:1-13.
27. Drazen JM, Israel E, O’Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340:197-206.
28. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclo-methasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999; 130:487-495.
29. Silverman ES, Drazen JM. The biology of 5-lipoxygenase: Function, structure, and regulatory mechanisms. Proc Assoc Am Physicians 1999; 111:525-536.
30. Silverman ES, Du J, De Sanctis GT, Radmark O, Samuelsson B, Drazen JM, Collins T. Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants. Am J Respir Cell Mol Biol 1998; 19:316-323.
31. Silverman ES, Du J, Williams AJ, Wadgaonkar R, Drazen JM, Collins T. cAMP-response-element-binding-protein-binding protein (CBP) and p300 are transcriptional coactivators of early growth response factor-1 (Egr-1). Biochem J 1998; 336:183-189.
32. In KH, Asano K, Beier D, Grobholz J, Finn PW, Silverman EK, Silverman ES, Collins T, Fischer AR, Keith TP, Serino K, Kim SW, De Sanctis GT, Yandava C, Pillari A, Rubin P, Kemp J, Israel E, Busse W, Ledford D, Murray JJ, Segal A, Tinkleman D, Drazen JM. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest1997; 99:1130-1137.
33. Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pillari A, Israel E, Schork N, Silverman ES, Katz DA, Drajesk J. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22:168-170.
34. Sampson AP, Siddiqui S, Buchanan D, Howarth PH, Holgate ST, Holloway JW, Sayers I. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 55(suppl 2):28-31.
35. Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 2000; 23:290-296.